Literature DB >> 29592

Relation of plasma prolactin to clinical response in schizophrenic patients.

P G Gruen, E J Sachar, N Altman, G Langer, M A Tabrizi, F S Halpern.   

Abstract

It has been suggested that, if dopamine antagonism is a necessary condition for the antischizophrenic action of neuroleptics, the prolactin response, as an index of dopamine blockade, would correlate with clinical response. Morning prolactin and clinical symptomatology were measured in 15 schizophrenic patients before neuroleptic therapy, and after three and six weeks of high-dose butaperazine or loxapine treatment. Prolactin levels were transiently elevated during the unmedicated admission period, probably reflecting a normal stress response. Prolactin increased in all patients during neuroleptic therapy. There was, however, no correlation between magnitude of prolactin changes and clinical response, probably because the prolactin response achieved a maximum at relatively low doses of neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 29592     DOI: 10.1001/archpsyc.1978.01770340072008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  13 in total

Review 1.  Neuroendocrine markers of CNS drug effects.

Authors:  E C Johnstone; I N Ferrier
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

2.  Prolactin responses to haloperidol in drug-free and treated schizophrenic patients.

Authors:  M Markianos; G Sakellariou; E Bistolaki
Journal:  J Neural Transm Gen Sect       Date:  1991

3.  Neuroendocrine tests during treatment with neuroleptic drugs: I. Plasma prolactin response to chlorpromazine challenge.

Authors:  T Kolakowska; S Fraser; M Franklin; J Knox
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

4.  Plasma levels of fluphenazine and prolactin in psychiatric patients.

Authors:  T Kitamura; D A McGovern; N W Imlah; D Wiles; A A Schiff
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988-09

Review 5.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.

Authors:  J G Csernansky; J Kaplan; C A Holman; L E Hollister
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

7.  Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients.

Authors:  M L Rao; W A Brown
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 8.  Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation.

Authors:  Uriel Halbreich
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate.

Authors:  D Wiles; M Franklin; S J Dencker; R Johansson; L Lundin; U Malm
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

10.  Pharmacological causes of hyperprolactinemia.

Authors:  Daria La Torre; Alberto Falorni
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.